San Diego scientists came away with more than $36 million in funding from the state’s stem cell institute at its board meeting April 29.
The California Institute for Regenerative Medicine, an agency established in 2005 after voters approved Proposition 71, agreed to provide $67.7 million in funding to companies across the state working to translate their discoveries into practical use. The most recent round of grants was directed at unmet medical needs or areas where new treatments have lagged.
In San Diego, privately held biotech Novocell, which is developing embryonic stem cell treatments for diabetes, will receive $5.4 million.
The Scripps Research Institute, which is studying various stem cell techniques used to treat arthritis and age-related macular degeneration, along with methods for ensuring the cells do no harm when implanted, will get $15.4 million.
Evan Snyder of the Burnham Institute for Medical Research will receive $3.6 million for his work in Parkinson’s disease.
Inder Verma of the Salk Institute for Biological Studies, who studies untreatable diseases of the blood and immune system, garnered $6.6 million.
And UC San Diego will receive $5.2 million for Yang Xu’s work in eliminating tumors seen in some stem cell therapies.
, Heather Chambers